Showing 2211-2220 of 2314 results for "".
- Verseon Presents Oral Drug Candidate for Diabetic Eye Diseasehttps://modernod.com/news/verseon-presents-oral-drug-candidate-for-diabetic-eye-disease/2476516/Verseon presented promising preclinical efficacy data for the first development candidate for clinical trials in their diabetic eye disease program at this week’s ARVO 2019 annual meeting in Vancouver. This new drug candidate for oral dosing could lead to the first real alternative to eye injecti
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Foundation Fighting Blindness to Host Annual Retinal Cell & Gene Therapy Innovation Summit Before ARVOhttps://modernod.com/news/foundation-fighting-blindness-to-host-annual-retinal-cell-gene-therapy-innovation-summit-before-arvo/2476488/The Foundation Fighting Blindness will co-host the 6th annual Retinal Cell and Gene Therapy Innovation Summit, in partnership with the Casey Eye Institute at Oregon Health & Science University. The summit–one of the world’s most comprehensive reviews (three dozen presenters) of ongoing
- PECAA Community Raises $116,000 for Optometry Giving Sighthttps://modernod.com/news/pecaa-community-raises-116000-for-optometry-giving-sight/2476452/PECAA, a nationwide doctor alliance group for independent eye care professionals, announced in March that through its Growing Through Giving Program, $116,000 had been raised in 2018 for the organization’s charity of
- AOA Announces 2019 National Optometry Hall of Fame Inducteeshttps://modernod.com/news/aoa-announces-2019-national-optometry-hall-of-fame-inductees/2476443/The American Optometric Association has announced the four ODs who will be inducted into the National Optometry Hall of Fame in 2019. This year’s inductees are: Murray Fingeret, OD; Donald Jarnagin, OD; Michael Mittelman, OD; and Glen Steele, OD.
- Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopiahttps://modernod.com/news/orasis-announces-initiation-of-phase-2b-clinical-study-of-csf-1-for-the-treatment-of-presbyopia/2476421/Orasis Pharmaceuticals announced the initiation of a phase 2b clinical study in the United States evaluating CSF-1 for the treatment of presbyopia. The phase 2b study is a multicenter, double-masked trial in the United States enrolling 150 participants with presbyopia to evaluate the efficacy and
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- Clinical Trials Show Safety and Efficacy of Inveltys for BID Treatment of Postoperative Inflammation and Painhttps://modernod.com/news/clinical-trials-show-safety-and-efficacy-of-kala-pharmaceuticals-inveltys-for-bid-treatment-of-postoperative-inflammation-and-pain/2476380/Kala Pharmaceuticals announced publication of two multicenter, randomized, double-masked, vehicle-controlled clinical trials of Inveltys (loteprednol etabonate ophthalmic suspension 1%) for treatment of inflammation and pain following cataract surgery. Inveltys, which utilizes AMPPLIFY D